Peer-reviewed veterinary case report
Toceranib treatment outcomes for dogs with bone cancer lung spread
By Kim, Changseok et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2017·Department of Clinical Studies (Kim, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
- Species:
- dog
Plain-English summary
A group of 20 dogs with advanced bone cancer (appendicular osteosarcoma) that had spread to the lungs were treated with a medication called toceranib (Palladia). Unfortunately, the results were not promising; only 10% of the dogs showed any improvement, with a median survival time of about 90 days. Most dogs did not respond well to the treatment, and the overall prognosis for this condition remains poor. If your dog has been diagnosed with metastatic osteosarcoma, it’s important to discuss treatment options and outcomes with your veterinarian.
People also search for: dog osteosarcoma treatment · toceranib for dogs cancer · dog lung cancer prognosis
Abstract
This retrospective study evaluated the outcomes of dogs with macroscopic pulmonary metastasis of appendicular osteosarcoma (OSA) treated with toceranib. Medical records of 20 dogs with macroscopic pulmonary metastasis of OSA that received toceranib were reviewed. The median dose and duration of toceranib administration were 2.52 mg/kg (range: 2.12 to 2.72 mg/kg) and 60 days (range: 17 to 231 days). The median progression free survival (PFS) and overall survival (OS) were 36 days (range: 17 to 231 days) and 90 days (range: 17 to 433 days), respectively. The clinical benefit rate was 10% (2/20; 1 partial response and 1 stable disease). The longest length of initial pulmonary nodules had significant impact on both PFS (= 0.01) and OS (= 0.02). The prognosis for dogs with metastatic OSA was poor with only 10% of dogs showing clinical benefit from toceranib. These results suggest that toceranib may not improve outcome in dogs with macroscopic pulmonary metastasis of OSA.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28966355/